Early Vasopressin Initiation Fails to Reduce Mortality in Septic Shock, JAMA Study Finds

Septic shock remains a major cause of mortality in intensive care units worldwide, requiring prompt recognition, fluid resuscitation, antibiotics, source control and vasopressor support. Norepinephrine is the preferred first-line vasopressor, while vasopressin is commonly added when blood pressure remains inadequate despite escalating norepinephrine doses. However, the optimal timing for introducing vasopressin remains uncertain. A new study published in JAMA suggests that initiating vasopressin at a lower norepinephrine dose does not significantly improve survival compared with a higher-dose initiation strategy.

The study, titled “Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial,” was conducted by Ithan D. Peltan and colleagues across 13 hospitals in Utah and Idaho, United States.

This pragmatic, cluster-randomised, crossover trial included 3,959 adults receiving vasopressors for septic shock between February 2024 and July 2025. Participating hospitals alternated monthly between two strategies for initiating fixed-dose vasopressin.

Under the lower-threshold strategy, vasopressin was recommended when norepinephrine or equivalent vasopressor requirements reached 0.1 µg/kg/min. Under the higher-threshold strategy, vasopressin was recommended at 0.4 µg/kg/min. The vasopressin infusion dose was 0.03 units/min.

The primary outcome was mortality at 28 days, while kidney replacement therapy-free days represented an important secondary outcome.

The investigators reported the following key findings:

• Among 3,959 patients, the median age was 68 years, and 48% were women.

• Vasopressin was administered to 52.4% of patients assigned to the lower-threshold strategy compared with 32.9% in the higher-threshold group.

• Mortality at 28 days was 31.8% (628/1,975) with the lower-threshold strategy versus 33.0% (655/1,984) with the higher-threshold strategy.

• The adjusted marginal odds ratio for mortality was 0.98 (95% CI, 0.87–1.06; P=0.62), indicating no statistically significant survival benefit.

• Kidney replacement therapy-free days were also similar between the groups.

Although the lower-threshold strategy resulted in earlier and more frequent vasopressin administration, this difference did not translate into improved clinical outcomes.

The findings are clinically important because vasopressin is frequently introduced to reduce catecholamine requirements, improve vascular tone and support haemodynamic stability in septic shock. Earlier initiation has been considered a potentially beneficial strategy, particularly in patients requiring progressively increasing norepinephrine doses.

However, the VASSPR trial challenges the assumption that earlier vasopressin administration necessarily improves survival. It suggests that a routine lower-dose trigger may not offer additional benefit over a higher-threshold strategy.

The investigators acknowledged important limitations. The trial was open-label, involved hospital-level treatment strategies rather than mandatory individual treatment assignments, and allowed clinician discretion. Adherence to the assigned strategies was imperfect. Consequently, the results do not exclude potential benefits in selected patient populations or with other initiation thresholds.

For practising intensivists, the findings reinforce the importance of individualised vasopressor management rather than relying exclusively on a fixed norepinephrine threshold. Haemodynamic response, tissue perfusion, cardiac function and the patient's overall clinical condition remain central to decision-making.

Clinical Message: Routine initiation of vasopressin at a norepinephrine-equivalent dose of 0.1 µg/kg/min, rather than 0.4 µg/kg/min, did not reduce 28-day mortality in this large pragmatic trial. The findings do not establish that vasopressin is ineffective; rather, they indicate that an earlier initiation strategy does not necessarily improve outcomes. Clinical judgement should continue to guide its use.

Reference:

Peltan ID, Groat D, Jacobs JR, et al. Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial. JAMA. Published online October 14, 2026.